Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Liabilities and Shareholders Equity (2019 - 2025)

Biodesix's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $87.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 10.04% year-over-year to $87.5 million; the TTM value through Dec 2025 reached $350.2 million, down 13.11%, while the annual FY2025 figure was $87.5 million, 10.04% down from the prior year.
  • Liabilities and Shareholders Equity reached $87.5 million in Q4 2025 per BDSX's latest filing, down from $88.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $115.8 million in Q2 2024 to a low of $61.7 million in Q1 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $88.7 million, with a median of $87.6 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 93.35% in 2021, then plummeted 46.62% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $76.1 million in 2021, then rose by 22.09% to $92.9 million in 2022, then increased by 6.66% to $99.1 million in 2023, then decreased by 1.87% to $97.2 million in 2024, then fell by 10.04% to $87.5 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Liabilities and Shareholders Equity are $87.5 million (Q4 2025), $88.7 million (Q3 2025), and $87.7 million (Q2 2025).